Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported 54-week Phase III data showing its experimental drug povorcitinib reduced disease activity in patients with moderate to severe hidradenitis suppurativa, the company announced …
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced executive leadership changes, including the appointment of Pablo J. Cagnoni, M.D., as president and global head of research and development, as the company …
Incyte Names Cagnoni President, Announces Leadership Changes Read More WILMINGTON, DE — The European Commission has approved Zynyz (retifanlimab), developed by Incyte (Nasdaq: INCY), in combination with carboplatin and paclitaxel for the first-line treatment of adults with metastatic or …
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it will present at three investor conferences in March, with live webcasts available on its investor relations website.
Incyte to Present at Three March Investor Conferences Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported fourth-quarter and full-year 2025 financial results on February 10, posting revenue growth of 28% in the quarter and 21% for the year, and …
Incyte Reports $5.14 Billion in 2025 Revenue, Issues 2026 Outlook Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it will release its fourth-quarter and full-year 2025 financial results before the market opens on Tuesday, February 10, followed by a conference call …
Incyte Sets February 10 Call to Unveil Q4 and Full-Year 2025 Results Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) on Thursday unveiled breakthrough results from a pivotal late-stage cancer trial that could redefine first-line treatment for one of the most aggressive forms of …
New Incyte Drug Combo Shows Power Against Deadly Lymphoma Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, placing the biopharmaceutical company in front of …
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, introducing …
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said Hervé Hoppenot recently resigned from its board of directors, effective immediately, formally ending a transition period that followed his long tenure as the …
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader Read More